Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of GTPase KRASG12D: a review of patent literature.

Expert opinion on therapeutic patents - 1 Aug 2024

Li Yuhang, Yang Le, Li Xiaoran, Zhang Xiaojin

Abstract excerpt

INTRODUCTION: KRAS is a critical oncogenic protein intricately involved in tumor progression, and the difficulty in targeting KRAS has led it to be classified as an 'undruggable target.' Among the various KRAS mutations, KRASG12D is highly prevalent and represents a promising therapeutic target, yet there are currently no approved inhibitors for it. AREA COVERED: This review summarizes numerous patents and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Drug Development
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patents as Topic

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Identifiers

PMID: 38884569
DOI: 10.1080/13543776.2024.2369630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of GTPase KRASG12D: a review of patent literature.PMID 38884569Read ↗

Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021).Semantic proximity Read ↗

Annual review of KRAS inhibitors in 2022.Semantic proximity Read ↗

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.Semantic proximity Read ↗

Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.Semantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.Semantic proximity Read ↗

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.